

Performance in Delivering Clinical Trials  
between 01 July 2019 - 30 June 2020

Research Ethics Committee Reference	IRAS #	Name of Trial	Target Number Of Patients Agreed?	Number Of Patients Agreed	Date Closed To Recruitment	Participants Recruited	Reason For Closure Of Trial	Comments
18/NW/0736	251961	Psoriasis Study of Health Outcomes (PSoHO) ? an International Observational Study of 3-Year Health Outcomes in the Biologic Treatment of Moderate-to-Severe Plaque Psoriasis	Number Agreed	10	06/12/2019	25	Recruitment Finished	
18/LO/0801	245146	A drug utilization study (DUS) of alirocumab in Europe to assess the effectiveness of the dosing recommendation to avoid very low LDL-C levels.	Number Agreed	2	24/01/2020	2	Recruitment Finished	
19/LO/0040	253233	A phase 4, multi-center, randomized, double-blind, placebo-controlled study of the impact of apremilast (CC-10004) on quality of life, efficacy, and safety in subjects with manifestations of plaque psoriasis and impaired quality of life	Number Agreed	1	28/02/2020	2	Recruitment Finished	
19/LO/0531	254272	A randomised, placebo-controlled, double-blind, interventional, multicenter, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-PAOD for the treatment of peripheral arterial occlusive disease (PAOD)	Number Agreed	4	15/05/2020	0	Withdrawn By Sponsor	Study withdrawn by the sponsor due to COVID-19